Our new website is coming soon, give it a try now and let us have your feedback. Take me to the Beta



Register
Login:
Share:
Email Facebook Twitter

Severn Trent CEO Liv Garfield speaking at the Hardman & Co Investor Forum Watch Now

Severn Trent CEO Liv Garfield speaking at the Hardman & Co Investor Forum
TSX Lithium explorer International Lithium Corp prepares to drill at Raleigh Lake


Sareum Share Chat (SAR)



Share Price: 0.415Bid: 0.40Ask: 0.43Change: -0.135 (-24.55%)Faller - Sareum
Spread: 0.03Spread as %: 7.50%Open: 0.425High: 0.45Low: 0.405Yesterday’s Close: 0.55


Share Discussion for Sareum




View all SAR Messages

Please login or register to post a message on Share Chat.

Posts per page:

Fadec92
Posts: 6,082
Premium Chat Member
Opinion:No Opinion
Price:0.65
RE: SRA737+LDG in SCLC!
19 May '19
 
Fadec92
Posts: 6,082
Premium Chat Member
Opinion:No Opinion
Price:0.65
SRA737+LDG in SCLC!
19 May '19
Not sure if the Video with Dr Sen has been posted before!

Dr Triparna Sen - MD Anderson Cancer Center, Houston, Texas

Efficacy and immune correlates of the SRA737 plus LDG (Low Dose gemcitabine) regimen in combination with anti-PD-L1 in an SCLC (Small Cell Lung Cancer) model

SCLC Accounts for 15% of all Lung Cancers cases in the US.

Dr Triparna Sen speaks to ecancer at the 2019 American Association for Cancer Research

(AACR) meeting about results from a study looking at the efficacy and correlates of immunity of the combination treatment involving CHK1 inhibitor SRA737 plus low dose gemcitabine with anti-PDL1 in a model of small cell lung cancer (SCLC).

She explains that SCLC is very good at hiding itself from the immune system causing most of the immunotherapy drugs so far to have modest benefit.

Dr Sen reports that this combination with immune checkpoint blockade and DNA damage repair completely regressed tumours in mouse models.

https://ecancer.org/video/7768/efficacy-and-immune-correlates-of-the-sra737-plus-ldg-regimen-in-combination-with-anti-pd-l1-in-an-sclc-model.php

https://www.proactiveinvestors.co.uk/companies/news/217748/sareums-flagship-chk1-inhibitor-shows-serious-lung-cancer-potential-in-mouse-models-217748.html




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk







Home  |  Contact Us  |  About Us  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy  |  Mobile Site  |  About this website design


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.